PMID- 33620682 OWN - NLM STAT- MEDLINE DCOM- 20211130 LR - 20231107 IS - 1699-3055 (Electronic) IS - 1699-048X (Print) IS - 1699-048X (Linking) VI - 23 IP - 8 DP - 2021 Aug TI - Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. PG - 1529-1541 LID - 10.1007/s12094-021-02558-0 [doi] AB - The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK-fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System. FAU - Garrido, P AU - Garrido P AUID- ORCID: 0000-0002-5899-6125 AD - Sociedad Espanola de Oncologia Medica (SEOM), Departamento de Oncologia Medica, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, CIBERONC, Madrid, Spain. pilargarridol@gmail.com. FAU - Hladun, R AU - Hladun R AD - Sociedad Espanola de Hematologia y Oncologias Pediatricas (SEHOP), Departamento de Oncologia, Hematologia y Trasplante de Progenitores Hematopoyeticos Pediatricos, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - de Alava, E AU - de Alava E AD - Sociedad Espanola de Anatomia Patologica (SEAP), Departamento de Citologia e Histologia Normal y Patologica, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS), CSIC, Facultad de Medicina, Universidad de Sevilla, CIBERONC, Sevilla, Spain. FAU - Alvarez, R AU - Alvarez R AD - Sociedad Espanola de Oncologia Medica (SEOM), Departamento de Oncologia Medica, Hospital Universitario Gregorio Maranon. Instituto Investigacion Sanitaria Gregorio Maranon (IISGM), Madrid, Spain. FAU - Bautista, F AU - Bautista F AD - Sociedad Espanola de Hematologia y Oncologias Pediatricas (SEHOP), Oncologia Pediatrica, Departamento de Hematologia y Trasplante de Celulas Madre Hematopoyeticas, Hospital Universitario Infantil Nino Jesus, Madrid, Spain. FAU - Lopez-Rios, F AU - Lopez-Rios F AD - Sociedad Espanola de Anatomia Patologica (SEAP), Departamento de Patologia, Laboratorio de Dianas Terapeuticas, Hospital Universitario HM Sanchinarro, CIBERONC, Madrid, Spain. FAU - Colomer, R AU - Colomer R AD - Sociedad Espanola de Oncologia Medica (SEOM), Departamento de Oncologia Medica, Hospital Universitario La Princesa, Universidad Autonoma de Madrid, Catedra UAM-Fundacion Instituto Roche de Medicina Personalizada de Precision, Madrid, Spain. FAU - Rojo, F AU - Rojo F AD - Sociedad Espanola de Anatomia Patologica (SEAP), Departamento de Patologia, IIS-Fundacion Universitaria Jimenez Diaz, CIBERONC, Madrid, Spain. LA - eng PT - Journal Article DEP - 20210223 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (Benzamides) RN - 0 (Indazoles) RN - 0 (Membrane Glycoproteins) RN - 0 (NTRK1 protein, human) RN - 0 (NTRK3 protein, human) RN - 0 (Oncogene Proteins, Fusion) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - EC 2.7.10.1 (Receptor, trkA) RN - EC 2.7.10.1 (Receptor, trkB) RN - EC 2.7.10.1 (Receptor, trkC) RN - EC 2.7.10.1 (tropomyosin-related kinase-B, human) RN - L5ORF0AN1I (entrectinib) RN - PF9462I9HX (larotrectinib) SB - IM MH - Adult MH - Age Factors MH - Benzamides/therapeutic use MH - Child MH - *Consensus MH - High-Throughput Nucleotide Sequencing MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Indazoles/therapeutic use MH - Membrane Glycoproteins/*genetics MH - Molecular Targeted Therapy MH - Neoplasms/diagnosis/*genetics/therapy MH - Oncogene Proteins, Fusion/analysis/*genetics MH - Protein Kinase Inhibitors/therapeutic use MH - Pyrazoles/therapeutic use MH - Pyrimidines/therapeutic use MH - Receptor, trkA/*genetics MH - Receptor, trkB/*genetics MH - Receptor, trkC/*genetics MH - Reverse Transcriptase Polymerase Chain Reaction MH - Societies, Medical MH - Spain PMC - PMC8238709 OTO - NOTNLM OT - Gene fusions OT - Molecular oncology OT - Mutations OT - Neoplasm OT - Target therapies COIS- The authors declare that, when writing and revising the text, they did not know the names of the pharmaceutical companies that provided financial support for this project, so this support has not influenced the content of this article. P Garrido declared advisory and consultancy honoraria from AbbVie, AstraZeneca, Blue-Print Medicines, BMS, Boehringer Ingelheim, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and Takeda; was compensated as speaker by AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Gilead, MSD, Pfizer, Roche, Rovi and Takeda. R Hladun declared she has not conflict of interest. E de Alava declared advisory and consultancy honoraria from Bayer, Lilly, and Roche; and was compensated as speaker by PharmaMar. R Alvarez declared advisory and consultancy honoraria from Boehringer Ingelheim, Lilly and PharmaMar; was compensated as speaker by Bayer, BMS, MSD, Novartis, PharmaMar and Roche; received research grants from Abbvie, AstraZeneca, Blue-Print Medicines, BMS, Janssen, Merrimack, Novartis, MSD, PharmaMar, Roche and Takeda; and benefitted from travel and accommodation expenses funded by PharmaMar and Roche. F Bautista declared advisory and consultancy honoraria from Amgen, Bayer, Eusa Pharma and Sanofi; was compensated as speaker by Amgen and Jazz Pharmaceuticals; and benefitted from travel and accommodation expenses funded by Eusa Pharma, Jazz Pharmaceuticals, Shire and Takeda. F Lopez-Rios declared advisory and consultancy honoraria from AstraZeneca, Bayer, BMS, Life Technologies, Lilly, MSD, Pfizer and Roche; and received research grants from Life Technologies, Lilly and Roche. R Colomer declared advisory and consultancy honoraria from Lilly, MSD, Roche and Servier; and was compensated as speaker by AstraZeneca, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, and Roche. F Rojo declared advisory and consultancy honoraria from Archer, AstraZeneca, BMS, Genomic Health, Guardant Health, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre and Roche; was compensated as speaker by AstraZeneca, BMS, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre and Roche; received research grants from Pfizer and Roche; and benefitted from travel and accommodation expenses funded by Novartis and Roche. EDAT- 2021/02/24 06:00 MHDA- 2021/12/01 06:00 PMCR- 2021/02/23 CRDT- 2021/02/23 12:17 PHST- 2020/11/30 00:00 [received] PHST- 2021/01/24 00:00 [accepted] PHST- 2021/02/24 06:00 [pubmed] PHST- 2021/12/01 06:00 [medline] PHST- 2021/02/23 12:17 [entrez] PHST- 2021/02/23 00:00 [pmc-release] AID - 10.1007/s12094-021-02558-0 [pii] AID - 2558 [pii] AID - 10.1007/s12094-021-02558-0 [doi] PST - ppublish SO - Clin Transl Oncol. 2021 Aug;23(8):1529-1541. doi: 10.1007/s12094-021-02558-0. Epub 2021 Feb 23.